So with inevitable resistant mechanisms, more and more clinical trials are seeking for potential biomarkers to predict the validity of the CDK4/6 inhibitors, thus bringing in more optionally effective therapy strategies to breast cancer patients, even to the currently incurable breast cancer patients. This evidence concerns the gene CDK4 and breast cancer.